Cell-free fetal DNA and RNA circulating in maternal blood can be used for the early non-
invasive prenatal diagnosis (NIPD) of an increasing number of genetic conditions, both for …

The discovery of circulating cell-free fetal DNA (cffDNA) in maternal plasma allowed for the
development of alternative methodologies that may facilitate safe non-invasive prenatal …

For over a decade, researchers have focused their attention on the development of non-
invasive prenatal diagnosis tests based on cell-free fetal DNA circulating in maternal blood …

Prenatal diagnosis and screening have undergone rapid development in recent years, with
advances in molecular technology driving the change. Noninvasive prenatal testing (NIPT) …

Objective The goal of this study is to provide an ethical framework for clinicians and
companies providing noninvasive prenatal testing using cell‐free fetal DNA or whole fetal …

The identification of cell‐free fetal DNA circulating in maternal blood combined with
technological developments, in particular next‐generation sequencing, is enabling the …

The new technology that will allow genetic testing of a fetus within the first trimester of
pregnancy by isolating cell‐free fetal DNA (cffDNA) in the mother's blood raises a range of …

Noninvasive prenatal screening using cell‐free DNA, which analyzes placental DNA
circulating in maternal blood to provide information about fetal chromosomal disorders early …

The discovery of cell free fetal DNA in maternal plasma has stimulated a rapid development
of non-invasive prenatal testing. The recent advent of massively parallel sequencing has …

Cell-free fetal nucleic acids circulating in the blood of pregnant women afford the opportunity
for early, noninvasive prenatal genetic testing. The predominance of admixed maternal …